Tofacitinib for psoriatic arthritis is efficacious in most patient-reported and clinical endpoints over time, and shows shorter initial and meaningful response times versus switching from placebo to the drug at month 3, noted researchers.
“The efficacy and safety of oral tofacitinib 5 mg or 10mg twice daily (BID) or adalimumab (40mg administered subcutaneously once every 2weeks [Q2W]) have been demonstrated in patients with active PsA and a previous inadequate response to conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (OPAL Broaden) or tumor necrosis factor